Abstract
Dosimetry for glass trans-arterial radioembolization (TARE) is commonly calculated via a uniform activity distribution model. Recent studies have demonstrated improved tumor response with increased dose to perfused area though no tumor dose threshold is established. This study evaluates dose to tumor and treatment response (mRECIST and LI-RADS criteria) after TARE for early-stage hepatocellular carcinoma (HCC) to determine a threshold tumor dose to predict a complete imaging response.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
